Association of Preexisting Heart Failure With Outcomes in Older Patients With Diffuse Large B-Cell Lymphoma.
Sign Up to like & getrecommendations! Published in 2023 at "JAMA cardiology"
DOI: 10.1001/jamacardio.2023.0303
Abstract: Importance Anthracycline-containing regimens are highly effective for diffuse large B-cell lymphoma (DLBCL); however, patients with preexisting heart failure (HF) may be less likely to receive anthracyclines and may be at higher risk of lymphoma mortality.… read more here.
Keywords: lymphoma; diagnosis; large cell; mortality ... See more keywords
Association of Disease Location and Treatment With Survival in Diffuse Large B-Cell Lymphoma of the Eye and Ocular Adnexal Region
Sign Up to like & getrecommendations! Published in 2017 at "JAMA Ophthalmology"
DOI: 10.1001/jamaophthalmol.2017.3286
Abstract: Importance Primary diffuse large B-cell lymphoma (DLBCL) of the ocular region is rare, and the utility of surgery and radiation therapy remains unresolved. Objective To explore the clinical characteristics and determine factors associated with overall… read more here.
Keywords: lymphoma; dlbcl; disease; uveal dlbcl ... See more keywords
A new prognostic model identifies patients aged 80 years and older with diffuse large B‐cell lymphoma who may benefit from curative treatment: A multicenter, retrospective analysis by the Spanish GELTAMO group
Sign Up to like & getrecommendations! Published in 2018 at "American Journal of Hematology"
DOI: 10.1002/ajh.25107
Abstract: The means of optimally managing very elderly patients with diffuse large B‐cell lymphoma (DLBCL) has not been established. We retrospectively analyzed 252 patients aged 80‐100 years, diagnosed with DLBCL or grade 3B follicular lymphoma, treated… read more here.
Keywords: lymphoma; treatment; prognostic model; large cell ... See more keywords
The association of physical activity before and after lymphoma diagnosis with survival outcomes
Sign Up to like & getrecommendations! Published in 2018 at "American Journal of Hematology"
DOI: 10.1002/ajh.25288
Abstract: The impact of physical activity (PA) on lymphoma survival is not known. The association of PA and change in PA with overall (OS), lymphoma‐specific (LSS) and event‐free (EFS) survival was evaluated in a prospective cohort… read more here.
Keywords: lymphoma; diagnosis; activity lymphoma; baseline ... See more keywords
Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B‐cell lymphoma
Sign Up to like & getrecommendations! Published in 2019 at "American Journal of Hematology"
DOI: 10.1002/ajh.25659
Abstract: This phase 1b/2, multicenter, open‐label study evaluated ibrutinib plus durvalumab in relapsed/refractory follicular lymphoma (FL) or diffuse large B‐cell lymphoma (DLBCL). Patients were treated with once‐daily ibrutinib 560 mg plus durvalumab 10 mg/kg every 2 weeks in… read more here.
Keywords: relapsed refractory; lymphoma; dlbcl; refractory follicular ... See more keywords
Aggressive lymphoma subtype is a risk factor for venous thrombosis. Development of lymphoma ‐ specific venous thrombosis prediction models
Sign Up to like & getrecommendations! Published in 2020 at "American Journal of Hematology"
DOI: 10.1002/ajh.25837
Abstract: Venous thromboembolic events (VTE) are a frequent complication of lymphoma. We conducted a retrospective analysis to compare VTE risk in diffuse large B‐cell lymphoma (DLBCL) and follicular lymphoma (FL). Subjects were randomly assigned to training… read more here.
Keywords: lymphoma; vte; risk; venous thrombosis ... See more keywords
Hodgkin lymphoma: A 2020 update on diagnosis, risk‐stratification, and management
Sign Up to like & getrecommendations! Published in 2020 at "American Journal of Hematology"
DOI: 10.1002/ajh.25856
Abstract: Hodgkin lymphoma (HL) is an uncommon B‐cell lymphoid malignancy affecting 8480 new patients annually and representing approximately 10% of all lymphomas in the United States. read more here.
Keywords: lymphoma; diagnosis risk; 2020 update; hodgkin lymphoma ... See more keywords
“Double hit” anaplastic large cell lymphoma with concurrent ALK and MYC rearrangements
Sign Up to like & getrecommendations! Published in 2020 at "American Journal of Hematology"
DOI: 10.1002/ajh.25980
Abstract: A 28-year-old man presented with a history of persistent left groin swelling for 2 years, which has shown slow growth in recent 2 months. He denied any B symptoms including fever, night sweats, and weight… read more here.
Keywords: lymphoma; double hit; image; alk ... See more keywords
Efficacy and safety of pioglitazone in a phase 1/2 imatinib discontinuation trial (EDI‐PIO) in chronic myeloid leukemia with deep molecular response
Sign Up to like & getrecommendations! Published in 2020 at "American Journal of Hematology"
DOI: 10.1002/ajh.25986
Abstract: with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190-2196. 3. Gambacorti-Passerini C, Messa C, Pogliani EM. Crizotinib in anaplastic large-cell lymphoma. N Engl J Med. 2011;364(8):775-776.… read more here.
Keywords: lymphoma; phase; gambacorti passerini; alk positive ... See more keywords
Ineffectiveness of high‐dose methotrexate for prevention of CNS relapse in diffuse large B‐cell lymphoma
Sign Up to like & getrecommendations! Published in 2021 at "American Journal of Hematology"
DOI: 10.1002/ajh.26181
Abstract: Central nervous system (CNS) relapse affects 5% of diffuse large B‐cell lymphoma (DLBCL) patients and portends a poor prognosis. Prophylactic intravenous high‐dose methotrexate (HD‐MTX) is frequently employed to reduce this risk, but there is limited… read more here.
Keywords: lymphoma; risk; cns relapse; cns ... See more keywords
A roadmap for clinical trial design in marginal zone lymphoma
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Hematology"
DOI: 10.1002/ajh.26706
Abstract: Significant advances in the drug development of indolent non-Hodg-kin lymphoma (iNHL) occurred over the last years expanding the landscape of treatment options. Several novel agents have been approved by the US Food and Drug Administration… read more here.
Keywords: lymphoma; design marginal; roadmap clinical; clinical trial ... See more keywords